JO3532B1 - الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها - Google Patents

الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها

Info

Publication number
JO3532B1
JO3532B1 JOP/2014/0080A JOP20140080A JO3532B1 JO 3532 B1 JO3532 B1 JO 3532B1 JO P20140080 A JOP20140080 A JO P20140080A JO 3532 B1 JO3532 B1 JO 3532B1
Authority
JO
Jordan
Prior art keywords
antibodies
diseases
attenuate
bind
inhibit
Prior art date
Application number
JOP/2014/0080A
Other languages
English (en)
Inventor
J Papadopoulos Nicholas
J Murphy Andrew
M Orengo Jamie
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Application granted granted Critical
Publication of JO3532B1 publication Critical patent/JO3532B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

يتعلق الاختراع الحالي بتوفير أجسام مضادة ترتبط بانترليوكين-33 (<span dir="LTR">IL-33</span>) و طرق استخدامها. يتضمن الاختراع الحالي أجسام مضادة تقوم بتثبيط أو تخفيف إرسال إشارة يتوسطها <span dir="LTR">IL-33</span>. يمكن أن تعمل الأجسام المضادة من الاختراع الحالي على منع التفاعل بين <span dir="LTR">IL-33 </span> و <span dir="LTR">ST2</span>. و بشكل بديل، تقوم بعض الأجسام المضادة من الاختراع الحالي بتثبيط أو تخفيف إرسال إشارة يتوسطها <span dir="LTR">IL-33</span> دون منع تفاعل <span dir="LTR">IL-33/ST2</span>. وفقا لتجسيدات محددة من الاختراع الحالي، تعد الأجسام المضادة عبارة عن أجسام مضادة بشرية تماما ترتبط ب <span dir="LTR">IL-33</span> بشري ذو ألفة عالية. تعد الأجسام المضادة من الاختراع الحالي مفيدة في علاج الأمراض و الاضطرابات المصاحبة لإرسال إشارة <span dir="LTR">IL-33</span> و/ أو التعبير الوراثي الخلوي <span dir="LTR">IL-33</span>، على سبيل المثال، الأمراض الالتهابية، أو أمراض الحساسية.
JOP/2014/0080A 2013-03-13 2014-03-09 الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها JO3532B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361778687P 2013-03-13 2013-03-13
US201361819018P 2013-05-03 2013-05-03

Publications (1)

Publication Number Publication Date
JO3532B1 true JO3532B1 (ar) 2020-07-05

Family

ID=50678269

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2014/0080A JO3532B1 (ar) 2013-03-13 2014-03-09 الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها

Country Status (29)

Country Link
US (5) US9453072B2 (ar)
EP (2) EP3683235A1 (ar)
JP (2) JP6479755B2 (ar)
KR (1) KR102103159B1 (ar)
CN (1) CN105051063B (ar)
AU (1) AU2014248839B2 (ar)
CA (1) CA2902172C (ar)
CL (2) CL2015002469A1 (ar)
DK (1) DK2970460T3 (ar)
EA (1) EA031745B1 (ar)
ES (1) ES2804592T3 (ar)
HK (1) HK1220467A1 (ar)
HR (1) HRP20200846T1 (ar)
HU (1) HUE051018T2 (ar)
IL (2) IL240354A0 (ar)
JO (1) JO3532B1 (ar)
LT (1) LT2970460T (ar)
MX (2) MX2015010599A (ar)
MY (1) MY174740A (ar)
PH (1) PH12015501656A1 (ar)
PL (1) PL2970460T3 (ar)
PT (1) PT2970460T (ar)
RS (1) RS60503B1 (ar)
SG (1) SG11201505745WA (ar)
SI (1) SI2970460T1 (ar)
TW (1) TWI633119B (ar)
UY (1) UY35417A (ar)
WO (1) WO2014164959A2 (ar)
ZA (1) ZA201505376B (ar)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX352889B (es) 2011-02-25 2017-12-13 Chugai Pharmaceutical Co Ltd Anticuerpo de fc especifico para fcyriib.
WO2013047748A1 (ja) 2011-09-30 2013-04-04 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
CN104080909A (zh) 2011-11-30 2014-10-01 中外制药株式会社 包含进入细胞内以形成免疫复合体的搬运体(载体)的药物
AR091069A1 (es) 2012-05-18 2014-12-30 Amgen Inc Proteinas de union a antigeno dirigidas contra el receptor st2
AR092177A1 (es) 2012-08-21 2015-03-25 Sanofi Sa Metodos para tratar o prevenir asma administrando un antagonista de il-4r
CN113831406A (zh) 2012-08-24 2021-12-24 中外制药株式会社 FcγRIIb特异性Fc区变体
DK2940135T5 (da) 2012-12-27 2021-09-20 Chugai Pharmaceutical Co Ltd Heterodimeriseret polypeptid
JO3532B1 (ar) 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
JP6404314B2 (ja) 2013-03-15 2018-10-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｉｌ−３３拮抗薬とその使用法
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
CA2908350C (en) 2013-04-02 2023-08-08 Futa Mimoto Fc region variant
CA3190793A1 (en) * 2013-12-26 2015-07-02 Mitsubishi Tanabe Pharma Corporation Human anti-il-33 neutralizing monoclonal antibody
SG10201805934RA (en) 2014-01-10 2018-08-30 Anaptysbio Inc Antibodies directed against interleukin-33 (il-33)
WO2015164354A1 (en) 2014-04-21 2015-10-29 The Childen's Hospital Of Philadelphia Compositions and methods for treating cytokine-related disorders
NO2785538T3 (ar) 2014-05-07 2018-08-04
US10093730B2 (en) 2014-11-10 2018-10-09 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
JP7231326B2 (ja) 2014-11-10 2023-03-01 ジェネンテック， インコーポレイテッド Ｉｌ－３３媒介性障害のための治療及び診断方法
PE20171111A1 (es) 2014-12-19 2017-08-07 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso
EA201791754A1 (ru) 2015-02-05 2019-01-31 Чугаи Сейяку Кабусики Кайся АНТИТЕЛА, СОДЕРЖАЩИЕ ЗАВИСЯЩИЙ ОТ КОНЦЕНТРАЦИИ ИОНОВ АНТИГЕНСВЯЗЫВАЮЩИЙ ДОМЕН, ВАРИАНТЫ Fc-ОБЛАСТИ, IL-8-СВЯЗЫВАЮЩИЕ АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ
AU2016226415B2 (en) * 2015-03-02 2021-09-09 180 Therapeutics Lp Method of treating a localized fibrotic disorder using a TNF receptor 2 antagonist
EP3733701A1 (en) * 2015-03-31 2020-11-04 MedImmune Limited A novel il33 form, mutated forms of il33, antibodies, assays and methods of using the same
JP6791874B2 (ja) * 2015-04-06 2020-11-25 メソ スケール テクノロジーズ エルエルシー 消耗品振動装置を含む電気化学発光を使用する分析を実行するための高スループットシステム
TW202330904A (zh) 2015-08-04 2023-08-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
KR20180053682A (ko) 2015-10-06 2018-05-23 리제너론 파아마슈티컬스, 인크. 인터루킨-33(il-33)-매개된 질환과 관련된 바이오마커 및 이의 용도
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
SG11201805900YA (en) * 2016-01-14 2018-08-30 Anaptysbio Inc Inhibition of allergic reaction using an il-33 inhibitor
SG10201913248VA (en) 2016-04-18 2020-02-27 Celldex Therapeutics Inc Agonistic antibodies that bind human cd40 and uses thereof
MA45294A (fr) * 2016-04-22 2019-02-27 Medimmune Llc Plasticité fonctionnelle d'ilc2, immunité et copd
MX2018013038A (es) 2016-04-27 2019-03-28 Pfizer Anticuerpos anti-il-33, composiciones, metodos y usos de los mismos.
WO2018025982A1 (ja) 2016-08-05 2018-02-08 中外製薬株式会社 Ｉｌ－８関連疾患の治療用又は予防用組成物
WO2018039499A1 (en) 2016-08-24 2018-03-01 Regeneron Pharmaceuticals, Inc. Host cell protein modification
BR112019006876A2 (pt) * 2016-10-13 2019-06-25 Symphogen As anticorpos e composições anti-lag-3
JOP20190093A1 (ar) * 2016-10-28 2019-04-25 Lilly Co Eli أجسام مضادة لـ il-33 واستخداماتها
TW202332696A (zh) * 2016-12-01 2023-08-16 美商再生元醫藥公司 治療發炎症狀的方法
CN110494453B (zh) 2017-02-10 2023-05-26 豪夫迈·罗氏有限公司 抗类胰蛋白酶抗体、其组合物及其用途
CN108456251A (zh) * 2017-02-21 2018-08-28 上海君实生物医药科技股份有限公司 抗pd-l1抗体及其应用
WO2018156180A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
SG11201909457XA (en) 2017-04-13 2019-11-28 Regeneron Pharma Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding il33 and il1rl1
JP2020527332A (ja) 2017-06-12 2020-09-10 ブルーフィン バイオメディシン， インコーポレイテッド 抗−ｉｌ１ｒａｐ抗体および抗体薬物コンジュゲート
BR112020000127A2 (pt) 2017-07-06 2020-07-07 Regeneron Pharmaceuticals, Inc. método para selecionar um hidrolisado de soja, e, glicoproteína
CN115920032A (zh) 2017-08-31 2023-04-07 田边三菱制药株式会社 含有il-33拮抗剂的子宫内膜异位症治疗剂
CN115925882A (zh) 2017-12-22 2023-04-07 瑞泽恩制药公司 用于表征药物产品杂质的系统和方法
BR112020013336A2 (pt) 2018-01-31 2020-12-01 Regeneron Pharmaceuticals, Inc. produto farmacêutico proteico, métodos para caracterizar as impurezas do produto farmacêutico proteico de alto peso molecular intermediário, para produção de um anticorpo, e para caracterizar as impurezas de fármaco com variação de carga, anticorpo, e, sistema para caracterizar impurezas de fármaco de alto peso molecular intermediário.
TW202311746A (zh) 2018-02-02 2023-03-16 美商再生元醫藥公司 用於表徵蛋白質二聚合之系統及方法
MA51741A (fr) 2018-02-09 2021-05-19 Hoffmann La Roche Procédés thérapeutiques et de diagnostic pour des maladies inflammatoires médiées par des mastocytes
AU2019227531A1 (en) 2018-02-28 2020-10-15 Regeneron Pharmaceuticals, Inc. Systems and methods for identifying viral contaminants
US11054389B2 (en) 2018-03-19 2021-07-06 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
IL307286A (en) * 2018-04-11 2023-11-01 Regeneron Pharma Methods and preparations for quantification of IL-33
TW202016125A (zh) 2018-05-10 2020-05-01 美商再生元醫藥公司 用於定量及調節蛋白質黏度之系統與方法
SG11202011970TA (en) 2018-08-27 2020-12-30 Regeneron Pharma Use of raman spectroscopy in downstream purification
TW202024639A (zh) 2018-08-30 2020-07-01 美商再生元醫藥公司 用於將蛋白質複合物定特徵之方法
AU2020208396A1 (en) 2019-01-16 2021-05-20 Regeneron Pharmaceuticals, Inc. Methods for identifying free thiols in proteins
TW202102260A (zh) * 2019-03-21 2021-01-16 美商再生元醫藥公司 含有抗ｉｌ－３３抗體之穩定調配物
JP2022530533A (ja) * 2019-05-01 2022-06-29 サノフィ・バイオテクノロジー Ｉｌ－３３アンタゴニストを投与することにより喘息を治療するまたは予防するための方法
WO2020231992A1 (en) 2019-05-13 2020-11-19 Regeneron Pharmaceuticals, Inc. Improved competitive ligand binding assays
CA3150234C (en) 2019-09-24 2023-12-12 Robert Stairs Systems and methods for chromatography use and regeneration
US11560595B2 (en) 2019-10-03 2023-01-24 Dasman Diabetes Institute Method for preventing progression to type II Diabetes
CA3158323A1 (en) 2019-11-04 2021-05-14 Medimmune Limited Methods of using il-33 antagonists
WO2021089559A1 (en) 2019-11-04 2021-05-14 Medimmune Limited Anti il-33 therapeutic agent fpr treating renal disorders
EP4065086A1 (en) 2019-11-25 2022-10-05 Regeneron Pharmaceuticals, Inc. Sustained release formulations using non-aqueous emulsions
AU2020415382A1 (en) * 2019-12-23 2022-08-18 Regeneron Pharmaceuticals, Inc. Methods for treating or preventing allergic asthma by administering an IL-33 antagonist and/or an IL-4R antagonist
MX2022008973A (es) 2020-01-21 2022-08-11 Regeneron Pharma Metodos de desglicosilacion para electroforesis de proteinas glicosiladas.
MX2022011156A (es) 2020-03-13 2022-10-13 Genentech Inc Anticuerpos anti-interleucina-33 y usos de estos.
US20230110203A1 (en) 2020-03-13 2023-04-13 Medimmune Limited Therapeutic methods for the treatment of subjects with risk alelles in il33
WO2021204707A1 (en) 2020-04-06 2021-10-14 Medimmune Limited Treating acute respiratory distress syndrome with il-33 axis binding antagonists
WO2021211416A1 (en) * 2020-04-13 2021-10-21 Maddon Advisors Llc Ace2- and tmprss2-targeted compositions and methods for treating covid-19
IL297841A (en) 2020-05-11 2023-01-01 Medimmune Ltd Formulations of anti-il-33 antibodies
MX2022014243A (es) * 2020-05-12 2022-12-02 Chia Tai Tianqing Pharmaceutical Group Co Ltd Proteina de union al antigeno st2.
KR20220022226A (ko) * 2020-08-18 2022-02-25 성균관대학교산학협력단 Il-33 항체 또는 이의 항원 결합 단편
WO2022047108A1 (en) 2020-08-31 2022-03-03 Regeneron Pharmaceuticals, Inc. Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants
CN114249825A (zh) * 2020-09-25 2022-03-29 三生国健药业（上海）股份有限公司 结合人il-33的抗体、其制备方法和用途
JP2023551446A (ja) 2020-11-25 2023-12-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 非水膜乳化を使用した持続放出製剤
EP4262757A1 (en) 2020-12-17 2023-10-25 Regeneron Pharmaceuticals, Inc. Fabrication of protein-encapsulating microgels
KR20230134117A (ko) 2021-01-20 2023-09-20 리제너론 파마슈티칼스 인코포레이티드 세포 배양물에서 단백질 역가를 개선시키는 방법
KR20230150300A (ko) 2021-03-03 2023-10-30 리제너론 파마슈티칼스 인코포레이티드 단백질 점도를 정량화하고 변경시키기 위한 시스템 및 방법
BR112023018665A2 (pt) 2021-03-26 2023-10-03 Regeneron Pharma Métodos e sistemas para desenvolvimento de protocolos de mistura
AU2022286340A1 (en) 2021-06-01 2024-01-04 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
CN113493513B (zh) * 2021-06-30 2022-07-12 深圳大学 抗人il-33中和性自身抗体及其制备方法和应用
CN113603775B (zh) * 2021-09-03 2022-05-20 江苏荃信生物医药股份有限公司 抗人白介素-33单克隆抗体及其应用
AR127006A1 (es) 2021-09-08 2023-12-06 Regeneron Pharma UN MÉTODO BASADO EN ESPECTROMETRÍA DE MASAS Y DE ALTO RENDIMIENTO PARA CUANTIFICAR ANTICUERPOS Y OTRAS PROTEÍNAS QUE CONTIENEN Fc
AU2022348521A1 (en) 2021-09-20 2024-04-04 Regeneron Pharmaceuticals, Inc. Methods of controlling antibody heterogeneity
AU2022359898A1 (en) 2021-10-07 2024-03-21 Regeneron Pharmaceuticals, Inc. Ph meter calibration and correction
TW202323817A (zh) 2021-10-07 2023-06-16 美商再生元醫藥公司 Ｐｈ建模及控制之系統及方法
US20230129265A1 (en) 2021-10-26 2023-04-27 Regeneron Pharmaceuticals, Inc. Systems and methods for generating laboratory water and distributing laboratory water at different temperatures
WO2023086807A1 (en) 2021-11-10 2023-05-19 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
WO2023166418A2 (en) * 2022-03-03 2023-09-07 Pfizer Inc. Multispecific antibodies and uses thereof
WO2023177836A1 (en) 2022-03-18 2023-09-21 Regeneron Pharmaceuticals, Inc. Methods and systems for analyzing polypeptide variants
TW202402790A (zh) 2022-03-25 2024-01-16 英商梅迪繆思有限公司 減少呼吸系統感染之方法
WO2024038185A1 (en) 2022-08-19 2024-02-22 Medimmune Limited Method of selecting patients for treatment with an il-33 axis antagonist

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US550362A (en) 1895-11-26 crosby
US1000056A (en) 1910-11-03 1911-08-08 Carlos Van Bergh Threshing-machine.
US1001164A (en) 1911-06-09 1911-08-22 Arthur W Porter Cotton-sweep.
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US5576191A (en) 1994-06-17 1996-11-19 Immunex Corporation Cytokine that binds ST2
AU2003299441A1 (en) 2002-12-19 2004-07-14 Centre National De La Recherche Scientifique - Cnrs Nf-hev compositions and methods of use
NZ549040A (en) 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
US7666622B2 (en) 2005-10-19 2010-02-23 Regeneron Pharmaceuticals, Inc. Monomeric self-associating fusion polypeptides and therapeutic uses thereof
WO2007140205A2 (en) 2006-05-24 2007-12-06 Biogen Idec Ma Inc. Methods of treating fibrosis
PT2374818E (pt) 2006-06-02 2013-02-13 Regeneron Pharma Anticorpos com elevada afinidade para o receptor il-6 humano
US7560530B1 (en) 2006-07-20 2009-07-14 Schering Corporation IL-33 receptor
IE20080331A1 (en) 2007-04-26 2009-07-08 Trinity College Dublin Products for altering cytokine activity and methods therefor
EP2069784A4 (en) 2007-05-18 2009-11-18 Medimmune Llc IL-33 IN INFLAMMATORY DISEASE
EP2211905A1 (en) 2007-10-26 2010-08-04 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of caspase i-dependent cytokines in the treatment of neurodegenerative disorders
WO2011031600A1 (en) 2009-09-10 2011-03-17 Schering Corporation Use of il-33 antagonists to treat fibrotic disease
US9090694B2 (en) 2012-04-30 2015-07-28 Janssen Biotech, Inc. ST2L antibody antagonists
AR091069A1 (es) 2012-05-18 2014-12-30 Amgen Inc Proteinas de union a antigeno dirigidas contra el receptor st2
JO3532B1 (ar) * 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
JP6404314B2 (ja) 2013-03-15 2018-10-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｉｌ−３３拮抗薬とその使用法
CA3190793A1 (en) 2013-12-26 2015-07-02 Mitsubishi Tanabe Pharma Corporation Human anti-il-33 neutralizing monoclonal antibody
SG10201805934RA (en) 2014-01-10 2018-08-30 Anaptysbio Inc Antibodies directed against interleukin-33 (il-33)

Also Published As

Publication number Publication date
IL261743B (en) 2020-11-30
TWI633119B (zh) 2018-08-21
HRP20200846T1 (hr) 2020-08-21
IL261743A (en) 2018-10-31
DK2970460T3 (da) 2020-06-02
PL2970460T3 (pl) 2020-10-05
US9453072B2 (en) 2016-09-27
EP3683235A1 (en) 2020-07-22
US20140271658A1 (en) 2014-09-18
SG11201505745WA (en) 2015-08-28
HK1220467A1 (zh) 2017-05-05
US20180251542A1 (en) 2018-09-06
EA031745B1 (ru) 2019-02-28
US10000564B2 (en) 2018-06-19
UY35417A (es) 2014-10-31
EP2970460A2 (en) 2016-01-20
CN105051063B (zh) 2019-08-16
KR102103159B1 (ko) 2020-05-29
US11104729B2 (en) 2021-08-31
AU2014248839A1 (en) 2015-08-20
RS60503B1 (sr) 2020-08-31
JP2019088311A (ja) 2019-06-13
PH12015501656B1 (en) 2015-10-19
JP2016513644A (ja) 2016-05-16
PT2970460T (pt) 2020-06-02
WO2014164959A3 (en) 2015-02-19
JP6845876B2 (ja) 2021-03-24
KR20150126598A (ko) 2015-11-12
EP2970460B1 (en) 2020-04-29
CA2902172A1 (en) 2014-10-09
MX2020012416A (es) 2021-02-09
SI2970460T1 (sl) 2020-07-31
AU2014248839B2 (en) 2019-01-03
MX2015010599A (es) 2015-12-15
US20200071396A1 (en) 2020-03-05
IL240354A0 (en) 2015-09-24
MY174740A (en) 2020-05-13
LT2970460T (lt) 2020-06-10
CL2015002469A1 (es) 2016-06-10
US10519230B2 (en) 2019-12-31
WO2014164959A2 (en) 2014-10-09
CA2902172C (en) 2024-04-02
TW201522370A (zh) 2015-06-16
EA201591716A1 (ru) 2016-07-29
US20210363236A1 (en) 2021-11-25
NZ710831A (en) 2021-04-30
ES2804592T3 (es) 2021-02-08
ZA201505376B (en) 2016-07-27
BR112015020470A2 (pt) 2017-10-10
CN105051063A (zh) 2015-11-11
US20160362487A1 (en) 2016-12-15
CL2018000101A1 (es) 2018-07-06
HUE051018T2 (hu) 2021-01-28
PH12015501656A1 (en) 2015-10-19
JP6479755B2 (ja) 2019-03-06

Similar Documents

Publication Publication Date Title
MX2020012416A (es) Anticuerpos dirigidos contra il-33 y sus usos.
PH12017500402A1 (en) Anti-glucagon antibodies and uses thereof
MX2018001532A (es) Anticuerpos anti-angptl8 y usos de estos.
PH12018500707A1 (en) Anti-human cd19 antibodies with high affinity
PH12015501493A1 (en) Anti-pdgfr-beta antibodies and uses thereof
PH12016500943A1 (en) Aplnr modulatros and uses thereof
MX364591B (es) Antagonistas de il-33 y usos de estos.
EA201691266A1 (ru) Анти-cd3 антитела и способы применения
WO2017015622A8 (en) Gdf11 binding proteins and uses thereof
PH12019500929A1 (en) Anti il-33 antibodies and uses thereof
NZ707086A (en) Anti-cd40 antibodies and methods of use
MY167920A (en) HUMAN ANTIBODIES TO GFRα3 AND METHODS OF USE THEREOF
MX2015012872A (es) Anticuerpos anti-tau y metodos de uso.
EA201592203A1 (ru) Способы лечения таупатии
GB2496337A (en) Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases
NZ715582A (en) Lectin-like oxidized ldl receptor 1 antibodies and methods of use
CL2015003174A1 (es) Anticuerpos anti-igf-1r con abolición de la unión al fcrn y su utilización en el tratamiento de enfermedades oculares vasculares
MX2015011518A (es) Agentes de enlace de met y usos de los mismos.
EA201691521A1 (ru) Антитела к интерлейкину-21
MX2019006676A (es) Anticuerpos anti-ccl2 para el tratamiento de la esclerodermia.
MX2018009218A (es) Anticuerpos de cgrp y sus usos.
EA202090453A3 (ru) Антитела к cd40